Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens

HIV Clinical Trials

Volumn 14, Issue 5, 2013, Pages 216-223

  Mills, Anthony ^a   Cohen, Calvin ^b   Dejesus, Edwin ^c   Brinson, Cynthia ^d   Williams, Scott ^e   Yale, Kitty ^e   Ramanathan, Srini ^e   Wang, Maggie ^e   White, Kirsten ^e   Chuck, Susan ^e   Cheng, Andrew ^e  

^a Anthony Mills MD Inc   (United States)

^b Boston Community Research Initiative of New England   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Central Texas Clinical Research   (United States)

^e GILEAD SCIENCES   (United States)

Author keywords

antiretroviral therapy; clinical trials; HIV 1; reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; VIRUS RNA;

ABNORMAL DREAMING; ADULT; ANXIETY; ARTICLE; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTRITIS; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIQUID CHROMATOGRAPHY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; NIGHTMARE; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOMNOLENCE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84886517499     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1405-216     Document Type: Article

References (28)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/guidelines. February 12, 2013.
2. Maggiolo F. Efavirenz: A decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64:910-928.
3. Waters L, Fisher M, Winston A, et al. A phase IV, doubleblind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011;25:65-71.
4. Elzi L, Marzolini C, Furrer H, et al. Treatment modifi cation in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
5. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates, management. A neurobehavioral review. AIDS Rev. 2009;11:103-109.
6. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147-154. (Pubitemid 46380808)
7. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz-and protease inhibitor-treated patients. HIV Clin Trials. 2005;6(4):187-196. (Pubitemid 41601130)
8. Zaccarelli M, Soldani F, Liuzzi G, et al. CNS side effects as main risk factor for efavirenz failure and transient HIVRNA elevation [abstract 720-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (CROI); February 24-28, 2002; Seattle, Washington. Abstract 720. Alexandria, VA: Foundation for Retrovirology and Human Health; 2002.
9. Mathias A, Menning M, Wei X, Dave A, Chuck S, Kearney BP. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract LBPE17.
10. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 effi cacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. AIDS. 2013;27(6):939-950.
11. Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: Pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81-91.
12. Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. US Prescribing Information. Foster City, CA: Gilead Sciences, Inc; June 2013.
13. Eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. EMA Prescribing Information. Stockley Park, UK: Gilead Sciences, Inc; January 2013.
14. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection. 2012 Recommendations of the International AIDS Society-USA Panel. JAMA. 2012;308(4):387-402.
15. British HIV Association. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. http://www.bhiva.org/ ClinicalGuidelines.aspx. Accessed September 13, 2013.
16. White K, Van Eygen V, Vingerhoets J, et al. Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naïve HIV-infected adults with ?100,000 c/mL baseline viral load. In: Program and abstracts of the 18th Annual Conference of the British HIV Association (BHIVA); April 18-20, 2012; Birmingham, UK. Abstract P187.
17. Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily TMC278 following administration of EFV in healthy volunteers. In: Program and abstracts of the18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27-March 2, 2011; Boston. Abstract 630.
18. Boffi to M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defi c Syndr. 2009;52(2):222-227.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. Division of Acquired Immune Defi ciency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 1. December 28, 2004. http://rsc.tech-res. com/Document/safetyandpharmacovigilance/Table- for-Grading-Severity-of-Adult-Pediatric-Adverse-Events. pdf. Accessed September 13, 2013.
21. Fisher M, Palella F, Tebas P, et al. SPIRIT: Switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression through Week 48. Presented at: 11th International Congress on Drug Therapy in HIV Infection. November 11-15, 2012; Glasgow, UK. Abstract P285.
22. Martinez E, Larrousse M, Llibre J, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS. 2010;24(11):1697-1707.
23. Mallolas J, Podzamczer D, Milinkovic A, et al. Effi cacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP study. J Acquir Immune Defi c Syndr. 2009;51(1):29-36.
24. Martinez E, Amaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodefi ciency virus infection. N Engl J Med. 2003;349(11):1036-1046. (Pubitemid 37087618)
25. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Effi cacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484-1492. (Pubitemid 46801594)
26. Alexander H, Seneviratne K, Kamuntu Y, et al. Rilpivirine in clinical practice. In: Program and abstracts of the19th Annual Conference of the British HIV Association (BHIVA); April 16-19, 2013; Manchester, UK. Abstract P147.
27. Phillips M, Saxon C, McBrien B, et al. Eviplera 1 year on: Experience of a large teaching hospital. In: Program and abstracts of the 19th Annual Conference of the British HIV Association (BHIVA); April 16-19, 2013; Manchester, UK. Abstract P156.
28. Taylor R, Darley A, Jayasuriya A. Early experience of rilpivirine use in a medium sized HIV cohort. In: Program and abstracts of the 19th Annual Conference of the British HIV Association (BHIVA); April 16-19, 2013; Manchester, UK. Abstract P163.